ANDEMBRY is the first and only prophylaxis
treatment that inhibits the hereditary angioedema
(HAE) cascade at the top
ANDEMBRY is the first and only prophylaxis treatment that inhibits the hereditary angioedema(HAE) cascade at the top
Connect with us
Meet with your CSL Behring Corporate Account Manager.
Schedule a meetingFormulary kit
Review product-specific resources for the first and only prophylaxis treatment that inhibits the HAE cascade at the top.
FormularyDecisions® members can download the ANDEMBRY Dossier [and additional ANDEMBRY resources] from FormularyDecisions.com.
About hereditary angioedema
Hereditary angioedema (HAE) is a rare, chronic, and potentially life-threatening genetic disorder that involves recurrent, unpredictable attacks of severe swelling (angioedema) throughout the body.1
HAE affects an estimated 1 in 50,000 people in the United States, with attacks often beginning around age 10 years.2,3 Patients with HAE are deficient in the C1 esterase inhibitor (C1-INH) protein or have malfunctioning C1-INH protein, which regulates the complement, contact, and coagulation cascades.2
HAE attacks can vary in number and severity, from several times per week to a few attacks per year.4,5 These attacks can affect multiple points of the body, with laryngeal attacks being especially risky.1,6 Severe laryngeal attacks may be fatal if untreated.2
Attacks may lead to emergency department (ED) visits or hospitalizations. Severe attacks are more than 100 times higher in cost for ED visits and hospitalizations than mild attacks.7
What is ANDEMBRY?
ANDEMBRY®(garadacimab-gxii) injection, for subcutaneous use, is an activated Factor XII (FXIIa) inhibitor (monoclonal antibody) indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.
Please see full prescribing information for ANDEMBRY.
What are the key benefits?
ANDEMBRY is the first and only prophylaxis treatment that inhibits the HAE cascade at the top.
Median reduction in monthly HAE attacks vs placebo (P<0.001)8*†
LS mean reduction in the number of HAE attacks vs placebo (P<0.001)8*†
Rapid onset of action from week 1* with sustained protection through 2 years—and counting9,10†
Once-monthly dosing from the start for all patients
*Data are from a 6-month, randomized, double-blind, placebo-controlled, parallel-group study (VANGUARD) of 64 patients aged 12 years and older with confirmed C1-
INH HAE. The primary endpoint was the monthly HAE attack rate at 6 months.
†One patient receiving placebo with <30 days of treatment was excluded from analysis as per CSP (n=24).
C1-INH, C1 esterase inhibitor; CSP, clinical study protocol; LS, least squares.
Want to learn more?
Meet with your CSL Behring Corporate
Account Manager.
Meet with your CSL Behring Corporate Account Manager.
Help us help you
Share your thoughts so we can further
tailor our content.
